Nanoparticle Albumin‑Bound Paclitaxel and Solvent-Based Paclitaxel as Chemotherapy Options for Patients With Advanced Gastric Cancer: A Systematic Review and Meta-Analysis.

Autor:	Gangannapalle M; Medicine, University of Perpetual Help System DALTA, Las Piñas, PHL., Shahnoor H; Internal Medicine, Deccan College of Medical Sciences, Hyderabad, IND., Sattar L; Medicine, Shadan Institute of Medical Sciences, Hyderabad, IND., Nagi TK; Internal Medicine, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, USA., Al-Tekreeti M; Public Health, American Public University System, Charles Town, USA., Khan MW; Medicine, Services Institute of Medical Sciences, Lahore, PAK., Haseeb MD; Neurology, Dow University of Health Sciences, Karachi, PAK., Khan A; Critical Care Medicine, United Medical and Dental College, Karachi, PAK.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Jul 11; Vol. 15 (7), pp. e41711. Date of Electronic Publication: 2023 Jul 11 (Print Publication: 2023).
DOI:	10.7759/cureus.41711
Abstrakt:	The aim of this study is to assess and compare the effectiveness and safety of nanoparticle albumin-bound paclitaxel (nab-PTX) and solvent-based PTX (sb-PTX) as treatment options for advanced gastric cancer. This meta-analysis was reported according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. We carried out a comprehensive search of PubMed, Google Scholar, and EMBASE from inception to June 15, 2023. The search strategy included the following keywords: "Nanoparticle albumin-bound paclitaxel," "solvent-based paclitaxel," and "advanced gastric cancer," along with their synonyms and medical subject heading (MeSH) terms. In this meta-analysis, the primary outcome was the comparison of overall survival and progression-free survival between the two groups. For safety purposes, we compared the risk of hematological and non-hematological events between the two groups. Four studies were included in this meta-analysis enrolling 1052 patients (483 received nb-PTX and 569 received sb-PTX). In terms of efficacy, nab-PTX showed favorable trends in overall survival and progression-free survival, despite no statistically significant differences being reported. The subgroup meta-analysis showed that nab-PTX seemed to have a better effect on peritoneal metastasis compared to sb-PTX. Regarding safety, the number of patients with neutropenia and leucopenia was significantly higher in the nab-PTX group compared to the sb-PTX group. However, the difference was statistically insignificant. Future research should focus on conducting more robust studies to further validate these findings and establish a stronger evidence base for the use of nab-PTX in this patient population. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Gangannapalle et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu